IL-13Rα2在胃癌及癌前病变中的表达及其临床意义OACSTPCD
Expression of IL-13Rα2 in gastric cancer and precancerous lesions and its clinical significance
目的:长期的炎症微环境促进胃上皮的萎缩、肠上皮化生、异型增生以及胃癌的发生,但目前其中机制尚不清楚.本研究旨在检测白细胞介素13受体α2(interleukin-13 receptor α2,IL-13Rα2)在胃癌及癌前病变中的表达情况,并探讨其临床意义.方法:210例活检组织分为慢性非萎缩性胃炎组(CNAG组,n=30)、慢性萎缩性胃炎伴肠上皮化生组(CAG/IM组,n=50)、胃黏膜低级别异型增生组(LGD组,n=30)、胃黏膜高级别异型增生组(HGD组,n=30)和胃癌组(GC组,n=70),采用免疫组织化学EnVision两步法检测上述各组中IL-13Rα2蛋白的表达.另外,再检测120例胃癌根治性组织中IL-13Rα2蛋白的表达,分析IL-13Rα2蛋白的表达与胃癌临床病理特征的关系.结果:CNAG组、CAG/IM组、LGD组、HGD组和GC组中IL-13Rα2的阳性率分别为3.3%、42.0%、13.3%、6.7%、84.3%;与CNAG组比较,CAG/IM组的IL-13Rα2阳性表达率升高(P<0.05);与CAG/IM组比较,LGD和HGD组的IL-13Rα2阳性表达率均降低(均P<0.05),GC组的IL-13Rα2阳性表达率升高(P<0.001).在根治性标本中,与癌旁组织相比,胃癌组织中IL-13Rα2的阳性表达率显著升高(P<0.001);临床病理分析显示:胃癌组织中IL-13Rα2阳性表达与Lauren分型有关[其在肠型胃癌中表达高于弥漫型、实性型和混合型胃癌,差异均有统计学意义(均P<0.001)];而与患者的年龄、性别、幽门螺杆菌感染状态、临床分期和淋巴结转移情况无明显相关性(均P>0.05).结论:IL-13Rα2在胃肠上皮化生中呈弱阳性表达,在胃癌中呈强阳性表达.IL-13Rα2在胃癌尤其是肠型胃癌中呈特异性高表达,有望成为胃癌治疗的新靶点.
Objective:The long-term inflammatory microenvironment promotes atrophy,intestinal metaplasia,dysplasia of the gastric epithelium,and the occurrence of gastric cancer,but the mechanism is still unclear.This study aims to detect the expression of interleukin-13 receptor α2(IL-13Rα2)in gastric and precancerous lesions and explore its clinical significance. Methods:A total of 210 biopsies were divided into 5 groups:a chronic non-atrophic gastritis group(CNAG group,n=30),a chronic atrophic gastritis with intestinal metaplasia group(CAG/IM group,n=50),a low-grade dysplasia group(LGD group,n=30),a high-grade dysplasia group(HGD group,n=30),and a gastric cancer group(GC group,n=70).The expression of IL-13Rα2 in these groups was detected using the immunohistochemical EnVision two-step method.Additionally,the expression of IL-13Rα2 in 120 cases from radical gastric cancer surgery was analyzed to examine the relationship between IL-13Rα2 expression and the clinicopathological features of gastric cancer. Results:The positive rates of IL-13Rα2 expression in the CNAG,CAG/IM,LGD,HGD,and GC groups were 3.3%,42%,13.3%,6.7%,and 84.3%,respectively.Compared to the CNAG group,the positive expression rate of IL-13Ra2 in the CAG/IM group increased significantly(P<0.05).Compared to the CAG/IM group,the positive rates in the LGD and HGD groups decreased(both P<0.05),whereas it increased significantly in the GC group(P<0.001).In radical specimens,the positive expression rate of IL-13Rα2 in gastric cancer tissues was significantly higher than that in adjacent non-tumor tissues(P<0.001).Clinicopathological analysis showed that the positive expression of IL-13Rα2 in gastric cancer was related to Lauren classification,which was higher in intestinal type than that in diffuse,solid,and mixed types(all P<0.001).There was no significant correlation between IL-13Rα2 expression and the patient's age,gender,Helicobacter pylori infection status,clinical staging,or lymph node metastasis(all P>0.05). Conclusion:IL-13Rα2 shows weak positive expression in gastric intestinal metaplasia and strong positive expression in gastric cancer.IL-13Rα2 is highly expressed specifically in intestinal-type gastric cancer and holds promise as a new therapeutic target for gastric cancer.
倪慕兰;李燕维;陈永东;王宇航
福建中医药大学附属福鼎医院病理科,福建 福鼎 355200
白细胞介素13受体α2胃癌癌前病变免疫组织化学
interleukin-13 receptor α2gastric cancerprecancerous lesionsimmunohistochemistry
《临床与病理杂志》 2024 (002)
199-206 / 8
福建中医药大学校管科研课题临床专项(XB2022053).This work was supported by the School Management Project on Clinical Research of Fujian University of Traditional Chinese Medicine,China(XB2022053).
评论